Skip to main content
SpringerLink
Log in

Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer

  • Gynecologic Cancers (RJ Morgan, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Epithelial ovarian cancer continues to be the leading cause of death due to gynecologic malignancy, and it is the fifth leading cause of cancer death in women in the USA and seventh worldwide. In most women with ovarian cancer, the disease is diagnosed at an advanced stage and primary cytoreductive surgery is considered standard of care. Traditionally, the gynecologic oncology literature supports the dictum that aggressive radical debulking to reduce intra-abdominal tumor burden to minimal or less than 1 cm of disease has significant impact on overall survival. However, the European Organization for Research and Treatment of Cancer (EORTC) trial found that survival after neoadjuvant followed by interval debulking surgery was similar to survival with the standard approach of primary surgery followed by chemotherapy. Many gynecologic oncologists have now adopted neoadjuvant chemotherapy for the treatment of stage IV ovarian cancer given the complex nature of this disease. Currently, there are conflicting results in the literature with regards to neoadjuvant chemotherapy versus primary debulking for stage IV ovarian cancer. While there is evidence that neoadjuvant treatment is not inferior to primary debulking, the literature also supports that maximizing debulking efforts with radical surgery can provide a survival benefit in patients with stage IV ovarian carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. American Cancer Society, searched 11 Jul 2015 http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-key-statistics

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.

    Article  PubMed  Google Scholar 

  3. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. Cancer incidence and mortality worldwide: IARC Lyon, France: International Agency for Research on Cancer; 2014. http://www.wcrf.org/int/cancer-facts-figures/worldwide-data, searched 1 Aug 2015

  4. National Cancer Institute, Surveillance, epidemiology and end result program. www.cancer.gov/statfacts/html/ovary.html, searched 11 Jul 2015

  5. Aletti G, Dowdy SC, Podratz KC, Cliby WA. Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol Oncol. 2007;105:84–9.

    Article  PubMed  Google Scholar 

  6. Winter WE, Maxwell L, Tian C, Sundborg MJ, Rose GS, Rose PG, et al. Tumor residual after surgical reduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2008;26(1):83–9.

    Article  PubMed  Google Scholar 

  7. Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol. 2007;25(20):2873–83.

    Article  PubMed  Google Scholar 

  8. Butler-Manuel S, Lippiatt J, Madhuri TK. Interval debulking surgery following neoadjuvant chemotherapy for stage IVB ovarian cancer using neutral argon plasma (Plasmajet™). Gynecol Oncol. 2014;135(3):622–3.

    Article  PubMed  Google Scholar 

  9. Juretzka MM, Abu-Rustem NR, Sonoda Y, Downey RJ, Flores RM, Park BJ, et al. The impact of video-assisted thoracic surgery (VATS) in patients with suspected ovarian malignancies and pleural effusions. Gynecol Oncol. 2007;104:670–4.

    Article  PubMed  Google Scholar 

  10. Miegs JV. Tumors of the pelvic organs. New York: Macmillian; 1934.

    Google Scholar 

  11. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101–4.

    PubMed  CAS  Google Scholar 

  12. Makar AP, Baekelandt M, Trope CG, Kristensen GB. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol. 1995;56:175–80.

    Article  PubMed  CAS  Google Scholar 

  13. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on the recurrence free interval and survival in small volume stage III epithelial ovarian cancer: a gynecologic oncology group study. Gynecol Oncol. 1992;47:159–66.

    Article  PubMed  CAS  Google Scholar 

  14. Akahira J, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H, et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol. 2001;81:398–03.

    Article  PubMed  CAS  Google Scholar 

  15. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170(4):974–9.

    Article  PubMed  CAS  Google Scholar 

  16. Yang XJ, Zheng FY, Xu YS, Ou RY. Ovarian cancer initially presenting with isolated ipsilateral superficial inguinal lymph node metastasis: a case study and review of the literature. J Ovarian Res. 2014;7:20.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Pereira A, Perez-Medina T, Magrina JF, Magtibay PM, Rodriguez-Tapia A, Perez-Milan F, et al. The impact of pelvic retroperitoneal invasion and distant nodal metastases in epithelial ovarian cancer. Surg Oncol. 2014;23:40–4.

    Article  PubMed  Google Scholar 

  18. Curtin JP, Malik R, Venkatraman ES, Barakat RR, Hoskins WJ. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol. 1997;64:9–12.

    Article  PubMed  CAS  Google Scholar 

  19. Munkarah AR, Hallum AV, Morris M, Burke TW, Levenback C, Atkinson EN, et al. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol. 1997;64:13–7.

    Article  PubMed  CAS  Google Scholar 

  20. Liu PC, Benjamin I, Morgan MA, King SA, Mikuta JJ, Rubin SC. Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol. 1997;64:4–8.

    Article  PubMed  CAS  Google Scholar 

  21. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72:278–87.

    Article  PubMed  CAS  Google Scholar 

  22. Aletti GD, Podratz KC, Cliby WA, Gostout BS. Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment. Gynecol Oncol. 2008;112:22–7.

    Article  PubMed  Google Scholar 

  23. Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012;124:10–4. Comparison of primary debulking surgery to neoadjuvant chemotherapy in advanced ovarian, tubal and peritoneal carcinoma based on EORTC-NCIC trial criteria.

    Article  PubMed  Google Scholar 

  24. Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, et al. Systemic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005;97(8):560–6.

    Article  PubMed  Google Scholar 

  25. Chang SJ, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol. 2012;19:4059–67.

    Article  PubMed  Google Scholar 

  26. Luyckx M, Leblanc E, Filleron T, Morice P, Darai E, Classe JM, et al. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice. Int J Gynecol Cancer. 2012;22(8):1337–43. A large multi-center study validating the prognostic factor of maximal cytoreduction in advanced stage ovarian cancer and its significant impact on survival.

    Article  PubMed  Google Scholar 

  27. Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;10(8):1–67.

    Google Scholar 

  28. Kang S, Kim TJ, Nam BH, Seo SS, Kim BG, Bae DS, et al. Preoperative serum CA-125 level and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. J Surg Oncol. 2010;101:13–7.

    Article  PubMed  CAS  Google Scholar 

  29. Gomez-Hildago NR, Martinez-Cannon BA, Nick AM, Lu KH, Sood AK, Coleman RL, et al. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol. 2015;137:553–8.

    Article  Google Scholar 

  30. Petrillo M, Vizzielli G, Fanfani F, Gallotta V, Cosentino F, Chiantera V, et al. Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept. Gynecol Oncol. 2015. doi:10.1016/j.ygyno.2015.07.095. Most recent update on staging laparoscopy prior to debulking surgery and the impact on patient management.

    Google Scholar 

  31. Fagotti A, Ferrandina G, Fanfani F, Garganese G, Vizzielli G, Carone VSalerno MG, et al. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol. 2008;199(6):642.e1–6.

    Article  Google Scholar 

  32. Fagotti A, Vizzielli G, Fanfani F, Costantini B, Ferrandina G, Gallotta V, et al. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience. Gynecol Oncol. 2013;131(2):341–6.

    Article  PubMed  CAS  Google Scholar 

  33. Vizzielli G, Costantini B, Tortorella L, Petrillo M, Fanfani F, Chiantera V, et al. Influence of intraperitoneal dissemination assessed by laparoscopy on prognosis of advanced ovarian cancer: an exploratory analysis of a single institution. Ann Surg Oncol. 2014;21:3970–7.

    Article  PubMed  Google Scholar 

  34. Rutten MJ, Leeflang MM, Kenter GG, Mol BW, Buist M. Laparoscopy for diagnosing resectability of disease in patients with ovarian cancer. Cochrane Database Syst Rev. 2014;2:CD009786. doi:10.1002/14651858.CD009786.pub2.

    PubMed  Google Scholar 

  35. Chi DS, Eisenhauer EI, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free survival and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114:26–31.

    Article  PubMed  Google Scholar 

  36. Harter P, Muallem ZM, Buhrmann C, Lorenz D, Kaub C, Hils R, et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol. 2011;121:615–9.

    Article  PubMed  Google Scholar 

  37. Perri T, Ben-Baruch G, Kalfon S, Beiner ME, Helpman L, Hogan LBD, et al. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction? Gynecol Oncol. 2013;131:27–31.

    Article  PubMed  Google Scholar 

  38. Diaz JP, Abu-Rustem NR, Sonoda Y, Downey RJ, Park BJ, Flores RM, et al. Video-assisted thoracic surgery (VATS) evaluation of pleural effusion in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients. Gynecol Oncol. 2010;116:483–8.

    Article  PubMed  Google Scholar 

  39. Klar M, Farthmann J, Bossart M, Stremmel C, Gitsch G, Passlick B, et al. Video-assisted thoracic surgery (VATS) evaluation of intrathoracic disease in patients with FIGO III and IV stage ovarian cancer. Gynecol Oncol. 2012;126:397–2.

    Article  PubMed  CAS  Google Scholar 

  40. Hoffman MS, Griffin D, Tebes S, Cardosi RJ, Martino MA, Fiorica JV, et al. Sites of bowel resected to achieve optimal ovarian cancer cytoreduction: implications regarding surgical management. Am J Obstet Gynecol. 2005;193(2):582–6.

    Article  PubMed  Google Scholar 

  41. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53.

    Article  PubMed  CAS  Google Scholar 

  42. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label randomized controlled, non-inferiority trial. Lancet. 2015;386:249–57.

    Article  PubMed  Google Scholar 

  43. Rosen B, Laframboise S, Ferguson S, Dodge J, Bernardini M, Murphy J, et al. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. Gynecol Oncol. 2014;134:462–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, NYU Langone Medical Center, NYU School of Medicine, 550 First Ave, NBV 9E2, New York, NY, 10016, USA

    Jing-Yi Chern ScM, MD & John P. Curtin MD

Authors
  1. Jing-Yi Chern ScM, MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John P. Curtin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John P. Curtin MD.

Ethics declarations

Conflict of Interest

Jing-Yi Chern and John P. Curtin declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Gynecologic Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chern, JY., Curtin, J.P. Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer. Curr. Treat. Options in Oncol. 17, 1 (2016). https://doi.org/10.1007/s11864-015-0380-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-015-0380-2

Keywords

Search

Navigation